ORIC Pharmaceuticals, Inc., a clinical-stage oncology company, announced a private placement of approximately 19.2 million shares of its common stock, offered at $6.50 per share, to institutional and accredited healthcare specialist investors. This sale represents an 18% premium to ORIC's 10-day trailing volume-weighted average price as of May 23, 2025. The financing, expected to close on May 29, 2025, is anticipated to generate gross proceeds of approximately $125 million. The funds will support the development of ORIC's clinical-stage product candidates and research programs, and are projected to sustain operations through the second half of 2027, including the primary endpoint readout from the ORIC-944 Phase 3 trial in prostate cancer. The financing round is led by SR One, with participation from notable investors including Point72, Viking Global Investors, and NEA.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.